$1.94 (1.04%)

Volume: 111.7k

Closed: Mar 21, 2023

Hollow Logo Score: -3.340
aTyr Pharma Stock
$1.94 (1.04%)

Volume: 111.7k

Closed: Mar 21, 2023

Score Hollow Logo -3.340

aTyr Pharma Stock Company Profile

3545 John Hopkins Court, Suite 250

San Diego CA 92121

858 731 8389


Industry: Biotechnology

Sector: Healthcare

aTyr Pharma


aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE